Göz Sorunları
Özet
Kanser tedavisi ve takibinde göz sağlığı sıklıkla göz ardı edilen bir konudur. Hastanın onkolojik tanısı, mevcut göz hastalıkları, diyabet ve hipertansiyon gibi eşlik eden sistemik hastalıklar ve doğal yaşlanma sürecinin etkileri hesaba katıldığında göz sorunları önemli hale gelir. Onkolojik bir hasta belirli bir oküler semptomla başvurduğunda, şikayetin malignitenin kendisinden mi, paraneoplastik sendromdan mı yoksa kanser tedavisinden mi kaynaklandığını belirlemek önemlidir. Tedavi sırasında akut yan etkileri düzenli olarak izlemek, uzun vadeli takipte fibrozis gibi kronik komplikasyonları ve yaşam boyu takip gerektiren riskleri belirlemek önemlidir. Hasta eğitimi, semptomlarla başa çıkmak ve erken dönemde bir doktora başvuru açısından önemlidir. Kanser takibindeki görme sorunları multidisipliner bir yaklaşım gerektirir. Hem immünoterapilerin hem de konvansiyonel kemoterapi ajanlarının oküler yan etki profilleri oldukça değişkendir. Onkolog ve oftalmolog her hasta için fayda ve zarar dengesini göz önünde bulundurarak ortak bir karara varmalıdır.
Eye health is often overlooked in cancer treatment and follow-up. When the patient's oncological diagnosis, existing eye diseases, accompanying systemic diseases such as diabetes and hypertension, and the effects of the natural aging process are taken into account, eye problems become important. When an oncologic patient presents with a specific ocular symptom, it is important to determine whether the complaint is due to the malignancy itself, a paraneoplastic syndrome or anticancer therapy. It is important to regularly monitor acute side effects during treatment, to evaluate chronic complications such as fibrosis in long-term follow-up, and to determine risk conditions that require lifelong follow-up. Patient education is very important for coping with symptoms and early referral to a doctor. Vision problems in cancer follow-up require a multidisciplinary approach. The ocular side effect profiles of both immunotherapies and conventional chemotherapy agents are quite variable, and the oncologist and ophthalmologist must reach a joint decision considering the balance of benefits and harms for each patient.
Referanslar
Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).
Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl). 2007 Sep;16(5):439-43. doi: 10.1111/j.1365-2354.2006.00763.x. PMID: 17760931.
Specenier P, Koppen C, Vermorken JB. Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol. 2007 May;18(5):961-2. doi: 10.1093/annonc/mdm116. Epub 2007 Apr 17. PMID: 17442661.
Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011 Feb 1;12(1):63-7. doi: 10.2165/11531920-000000000-00000. PMID: 20726623.
Bouché O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 2005 Oct;16(10):1711-2. doi: 10.1093/annonc/mdi300. Epub 2005 Jun 21. PMID: 15972283.
Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl). 2007 Sep;16(5):439-43. doi: 10.1111/j.1365-2354.2006.00763.x. PMID: 17760931.
Vaccaro M, Pollicino A, Barbuzza O, Guarneri B. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol. 2009 Apr;34(3):402-3. doi: 10.1111/j.1365-2230.2008.02842.x. Epub 2008 Dec 22. PMID: 19120397.
Rodriguez NA, Ascaso FJ. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer. J Clin Oncol. 2011 Jun 20;29(18):e532-3. doi: 10.1200/JCO.2011.34.6858. Epub 2011 Apr 11. PMID: 21483009.
Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008 Jun;27(5):612-4. doi: 10.1097/ICO.0b013e318166f483. PMID: 18520515.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf (Accessed on September 02, 2021).
Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005 Jul;19(7):729-38. doi: 10.1038/sj.eye.6701630. PMID: 15688060.
Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013 Apr;21(4):1167-74. doi: 10.1007/s00520-012-1645-y. Epub 2012 Nov 15. PMID: 23151647.
Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008 Jun;27(5):612-4. doi: 10.1097/ICO.0b013e318166f483. PMID: 18520515.
Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, Molina-Prat N. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012 Sep;119(9):1798-802. doi: 10.1016/j.ophtha.2012.03.002. Epub 2012 May 12. PMID: 22584020.
Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea. 2009 Jul;28(6):706-7. doi: 10.1097/ICO.0b013e31818fdbc6. PMID: 19512896.
Shin E, Lim DH, Han J, Nam DH, Park K, Ahn MJ, Kang WK, Lee J, Ahn JS, Lee SH, Sun JM, Jung HA, Chung TY. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmol. 2020 Jan 9;20(1):19. doi: 10.1186/s12886-019-1285-9. PMID: 31918686; PMCID: PMC6953164.
Lazcluze: Highlights of prescribing information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbl.pdf (Accessed on August 26, 2024).
Lim LT, Blum RA, Cheng CP, Hanifudin A. Bilateral anterior uveitis secondary to erlotinib. Eur J Clin Pharmacol. 2010 Dec;66(12):1277-8. doi: 10.1007/s00228-010-0873-7. Epub 2010 Aug 3. PMID: 20680254.
Ali K, Kumar I, Usman-Saeed M, Usman Saeed M. Erlotinib-related bilateral anterior uveitis. BMJ Case Rep. 2011 May 24;2011:bcr0320113988. doi: 10.1136/bcr.03.2011.3988. PMID: 22694887; PMCID: PMC3109688.
Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006 Sep;55(3):429-37. doi: 10.1016/j.jaad.2006.04.062. Epub 2006 Jul 13. PMID: 16908348.
Yin VT, Wiraszka TA, Tetzlaff M, Curry JL, Esmaeli B. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. Ophthalmic Plast Reconstr Surg. 2015 Jul-Aug;31(4):e112-5. doi: 10.1097/IOP.0000000000000140. PMID:
Chen P, Chen F, Zhou B. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clin Exp Dermatol. 2019 Apr;44(3):243-251. doi: 10.1111/ced.13751. Epub 2018 Oct 2. PMID: 30280426.
Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16. PMID: 22805291.
LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9. PMID: 20215549.
Niro A, Strippoli S, Alessio G, Sborgia L, Recchimurzo N, Guida M. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series. Am J Ophthalmol. 2015 Nov;160(5):959-967.e1. doi: 10.1016/j.ajo.2015.07.035. Epub 2015 Jul 29. PMID: 26231307.
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr 15;16(8):2450-7. doi: 10.1158/1078-0432.CCR-09-1920. Epub 2010 Mar 23. PMID: 20332327.
Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014 Jul;25(7):1437-1441. doi: 10.1093/annonc/mdu169. Epub 2014 May 26. PMID: 24864047.
United States Prescribing Information for trametinib available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1 (Accessed on February 28, 2017).
MEKINIST- trametinib tablet, film coated. MEKINIST- trametinib powder, for solution. United States prescribing information. Revised February 27, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1.
BALVERSA (erdafitinib) tablets, for oral use. United States prescribing information. Revised April 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf.
PEMAZYRE (pemigatinib) tablets, for oral use. United States prescribing information. Revised April 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf.
ICLUSIG- ponatinib hydrochloride tablet, film coated. United States prescribing information. Revised November 10, 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac.
Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012 Fall;6(4):423-6. doi: 10.1097/ICB.0b013e31824f7130. PMID: 25389947.
United States Prescribing Information for avelumab available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118 (Accessed on April 17, 2017).
United States Prescribing Information for atezolizumab available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee (Accessed on April 17, 2017).
Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018 Jun;38(6):1063-1078. doi: 10.1097/IAE.0000000000002181. PMID: 29689030.
Francis JH, Jaben K, Santomasso BD, Canestraro J, Abramson DH, Chapman PB, Berkenstock M, Aronow ME. Immune Checkpoint Inhibitor-Associated Optic Neuritis. Ophthalmology. 2020 Nov;127(11):1585-1589. doi: 10.1016/j.ophtha.2020.05.003. Epub 2020 May 8. PMID: 32437864; PMCID: PMC8488949.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. PMID: 25891173.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. doi: 10.1200/JCO.21.02786. PMID: 34724392.
Crizotinib capsules. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf (Accessed on June 21, 2019).
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588. PMID: 20979469; PMCID: PMC3014291.
Chun SG, Iyengar P, Gerber DE, Hogan RN, Timmerman RD. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol. 2015 Feb 10;33(5):e25-6. doi: 10.1200/JCO.2013.49.1985. Epub 2014 Mar 10. PMID: 24616318.
Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014 Oct;19(10):e5-11. doi: 10.1634/theoncologist.2014-0241. Epub 2014 Aug 28. PMID: 25170012; PMCID: PMC4201002.
Pyrhönen S, Ellmén J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999 Jul;56(2):133-43. doi: 10.1023/a:1006250213357. PMID: 10573106.
Muftuoglu O, Uçakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens. 2006 Sep;32(5):228-32. doi: 10.1097/01.icl.0000201396.74294.85. PMID: 16974155.
Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. Semin Ophthalmol. 2012 Jan-Mar;27(1-2):27-8. doi: 10.3109/08820538.2011.631510. PMID: 22352823.
Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978 Mar;62(3):315-20. PMID: 647693.
Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007 Jul;144(1):126-8. doi: 10.1016/j.ajo.2007.03.023. PMID: 17601434.
Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am. 2009 Feb;23(1):109-14, ix. doi: 10.1016/j.hoc.2008.11.003. PMID: 19248974.
Radaelli F, Vener C, Ripamonti F, Iurlo A, Colombi M, Artoni A, Reda G, Deliliers GL. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol. 2007 Dec;86(5):390-3. doi: 10.1007/BF02983993. PMID: 18192104.
Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg. 2005 Dec;31(12):2427-8. doi: 10.1016/j.jcrs.2005.10.029. PMID: 16473243.
Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003 Aug;19(4):371-5. doi: 10.1089/108076803322279426. PMID: 12964961.
Govind Babu K, Attili VS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007 Feb;27(1):43-4. doi: 10.1007/s10792-007-9038-9. Epub 2007 Apr 5. PMID: 17410337.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825; PMCID: PMC10592645.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19. PMID: 31229240; PMCID: PMC6860022.
Hofstra LS, de Vries EG, Willemse PH. Ophthalmic toxicity following paclitaxel infusion. Ann Oncol. 1997 Oct;8(10):1053. doi: 10.1023/a:1008249230056. PMID: 9402182.
eitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003 Apr;80(4):277-9. doi: 10.1097/00006324-200304000-00004. PMID: 12692483.
Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom. 2012 Mar;95(2):233-6. doi: 10.1111/j.1444-0938.2011.00672.x. Epub 2011 Oct 25. PMID: 22023333.
Hamersley J, Luce JK, Florentz TR, Burkholder MM, Pepper JJ. Excessive lacrimation from fluorouracil treatment. JAMA. 1973 Aug 13;225(7):747-8. doi: 10.1001/jama.1973.03220340051021. PMID: 4740487.
Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma. 2010 Jan;51(1):50-60. doi: 10.3109/10428190903419130. PMID: 20055658.
Guthoff T, Tietze B, Meinhardt B, Becher J, Guthoff R. Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica. 2010;224(5):308-11. doi: 10.1159/000298751. Epub 2010 Mar 23. PMID:
Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983 Aug;62(2):361-9. PMID: 6223674.
Spiers AS, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Haematol. 1984 Feb;32(2):130-4. doi: 10.1111/j.1600-0609.1984.tb02167.x. PMID: 6608139.
Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol. 1989 Dec 15;108(6):709-11. doi: 10.1016/0002-9394(89)90866-0. PMID: 2596552.
Das A, Ranjan R, Shah PK, Narendran V. Paclitaxel- and/or cyclophosphamide-induced severe ischaemic retinopathy. Clin Exp Ophthalmol. 2020 Nov;48(8):1113-1115. doi: 10.1111/ceo.13854. Epub 2020 Sep 13. PMID: 32892426.
Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol. 1997 Apr;28(4):310-3. doi: 10.1002/(sici)1096-911x(199704)28:4<310::aid-mpo12>3.0.co;2-g. PMID: 9078334.
BLACK RL, OGLESBY RB, VON SALLMANN L, BUNIM JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 1960 Sep 10;174:166-71. doi: 10.1001/jama.1960.63030020005014. PMID: 13801171.
Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009 Jul;68(7):1119-24. doi: 10.1136/ard.2008.092163. Epub 2008 Aug 6. PMID: 18684744.
Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009 Jul;68(7):1119-24. doi: 10.1136/ard.2008.092163. Epub 2008 Aug 6. PMID: 18684744.
Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol. 2002;514:109-24. doi: 10.1007/978-1-4615-0121-3_7. PMID: 12596918.
Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol. 2008 Mar;28(1):58-68. doi: 10.1097/WNO.0b013e3181677fcc. PMID: 18347462.
Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol. 1990 Aug;28(2):162-7. doi: 10.1002/ana.410280208. PMID: 2171418.
Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003 Jan-Feb;48(1):12-38. doi: 10.1016/s0039-6257(02)00416-2. PMID: 12559325.
Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009 Mar;8(5):410-4. doi: 10.1016/j.autrev.2009.01.002. Epub 2009 Jan 23. PMID: 19168157; PMCID: PMC2680817.
Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol. 2001 Jun;131(6):806-8. doi: 10.1016/s0002-9394(00)00925-9. PMID: 11384586.
Katsuta H, Okada M, Nakauchi T, Takahashi Y, Yamao S, Uchida S. Cancer-associated retinopathy associated with invasive thymoma. Am J Ophthalmol. 2002 Sep;134(3):383-9. doi: 10.1016/s0002-9394(02)01598-2. PMID: 12208250.
Yamada G, Ohguro H, Aketa K, Itoh T, Shijubo N, Takahashi H, Fujiwara O, Satoh M, Ohtsuka K, Abe S. Invasive thymoma with paraneoplastic retinopathy. Hum Pathol. 2003 Jul;34(7):717-9. doi: 10.1016/s0046-8177(03)00183-7. PMID: 12874770.
Espandar L, O'Brien S, Thirkill C, Lubecki LA, Esmaeli B. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol. 2007 Jul;83(3):295-302. doi: 10.1007/s11060-006-9326-7. Epub 2007 Jan 25. PMID: 17252185.
Chang PY, Yang CH, Yang CM. Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review. Retina. 2005 Dec;25(8):1093-6. doi: 10.1097/00006982-200512000-00020. Erratum in: Retina. 2006 Mar;26(3):377. Yang, Chang-May [corrected to Yang, Chung-May]. PMID: 16340542.
Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol. 2004 Jun 4;4:5. doi: 10.1186/1471-2415-4-5. PMID: 15180904; PMCID: PMC446200.
Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol. 1992 Jan;110(1):48-53. doi: 10.1001/archopht.1992.01080130050025. PMID: 1310001.
Mahdi N, Faia LJ, Goodwin J, Nussenblatt RB, Sen HN. A case of autoimmune retinopathy associated with thyroid carcinoma. Ocul Immunol Inflamm. 2010 Aug;18(4):322-3. doi: 10.3109/09273941003802379. PMID: 20662664.
Espandar L, O'Brien S, Thirkill C, Lubecki LA, Esmaeli B. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol. 2007 Jul;83(3):295-302. doi: 10.1007/s11060-006-9326-7. Epub 2007 Jan 25. PMID: 17252185.
Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol. 1997 Jun;17(2):77-83. PMID: 9176775.
Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999 Apr;117(4):471-7. doi: 10.1001/archopht.117.4.471. PMID: 10206574.
Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001 Sep;21(3):173-87. doi: 10.1097/00041327-200109000-00004. PMID: 11725182.
Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, Engst R, Thirkill CE, Ring J. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol. 1997 Sep;137(3):457-60. PMID: 9349350.
Lu Y, Jia L, He S, Hurley MC, Leys MJ, Jayasundera T, Heckenlively JR. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009 Dec;127(12):1572-80. doi: 10.1001/archophthalmol.2009.311. PMID: 20008709; PMCID: PMC4618318.
Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pföhler C. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol. 2005 May;152(5):931-8. doi: 10.1111/j.1365-2133.2005.06480.x. PMID: 15888149.
Shimazaki K, Jirawuthiworavong GV, Heckenlively JR, Gordon LK. Frequency of anti-retinal antibodies in normal human serum. J Neuroophthalmol. 2008 Mar;28(1):5-11. doi: 10.1097/WNO.0b013e318167549f. PMID: 18347451.
Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol. 2008 Mar;28(1):23-6. doi: 10.1097/WNO.0b013e31816754c4. PMID: 18347454.
Jacobzone C, Cochard-Marianowski C, Kupfer I, Bettembourg S, Dordain Y, Misery L, Cochener B, Sassolas B. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol. 2004 Oct;140(10):1258-61. doi: 10.1001/archderm.140.10.1258. PMID: 15492190
Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma. Neurology. 1984 Jun;34(6):788-91. doi: 10.1212/wnl.34.6.788. PMID: 6539443.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001 Feb;49(2):146-54. PMID: 11220734.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003 Jul;54(1):38-50. doi: 10.1002/ana.10587. PMID: 12838519.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001 Feb;49(2):146-54. PMID: 11220734.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003 Jul;54(1):38-50. doi: 10.1002/ana.10587. PMID: 12838519.
Murakami Y, Yoshida S, Yoshikawa H, Yamaji Y, Ikeda Y, Ueno A, Ishibashi T. CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond). 2007 Jun;21(6):860-2. doi: 10.1038/sj.eye.6702730. Epub 2007 Feb 2. PMID: 17277748.
Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond). 2008 Sep;22(9):1191-3. doi: 10.1038/sj.eye.6702959. Epub 2007 Aug 24. Erratum in: Eye (Lond). 2009 Sep;23(9):1883. Pulido, J [added]. PMID: 17721501.
Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond). 2008 Sep;22(9):1191-3. doi: 10.1038/sj.eye.6702959. Epub 2007 Aug 24. Erratum in: Eye (Lond). 2009 Sep;23(9):1883. Pulido, J [added]. PMID: 17721501.
Ducray F, Roos-Weil R, Garcia PY, Slesari J, Heinzlef O, Chatelain D, Toussaint P, Roullet E, Honnorat J. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):325-7. doi: 10.1136/jnnp.2006.097972. PMID: 17308295; PMCID: PMC2117653.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003 Jul;54(1):38-50. doi: 10.1002/ana.10587. PMID: 12838519.
Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond). 2008 Sep;22(9):1191-3. doi: 10.1038/sj.eye.6702959. Epub 2007 Aug 24. Erratum in: Eye (Lond). 2009 Sep;23(9):1883. Pulido, J [added]. PMID: 17721501.
Damek DM. Paraneoplastic Retinopathy/Optic Neuropathy. Curr Treat Options Neurol. 2005 Jan;7(1):57-67. doi: 10.1007/s11940-005-0007-1. PMID: 15610708.
O'Neal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol. 2003 Nov-Dec;48(6):613-25. doi: 10.1016/j.survophthal.2003.08.005. PMID: 14609707.
Duong HV, McLean IW, Beahm DE. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol. 2006 Oct;142(4):693-5. doi: 10.1016/j.ajo.2006.04.059. PMID: 17011873.
Saito W, Kase S, Yoshida K, Ohguro H, Yokoi M, Iwaki H, Ohno S. Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy. Am J Ophthalmol. 2005 Nov;140(5):942-5. doi: 10.1016/j.ajo.2005.05.048. PMID: 16310487.
Sen J, Clewes AR, Quah SA, Hiscott PS, Bucknall RC, Damato BE. Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation. Clin Exp Ophthalmol. 2006 Mar;34(2):156-8. doi: 10.1111/j.1442-9071.2006.01145.x. PMID: 16626431.
